This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.

Diamantopoulos, A., Benucci, M., Capri, S., Berger, W., Wintfeld, N., Giuliani, G., Ricciardi, W., Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy, <<JOURNAL OF MEDICAL ECONOMICS>>, 2012; 15 (3): 576-585. [doi:10.3111/13696998.2012.665110] [http://hdl.handle.net/10807/40265]

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

Ricciardi, Walter
2012

Abstract

This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.
2012
Inglese
Diamantopoulos, A., Benucci, M., Capri, S., Berger, W., Wintfeld, N., Giuliani, G., Ricciardi, W., Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy, <<JOURNAL OF MEDICAL ECONOMICS>>, 2012; 15 (3): 576-585. [doi:10.3111/13696998.2012.665110] [http://hdl.handle.net/10807/40265]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/40265
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 42
  • ???jsp.display-item.citation.isi??? ND
social impact